Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ulla Sammer is active.

Publication


Featured researches published by Ulla Sammer.


PLOS ONE | 2015

Do We Need Surveillance Urethro-Cystoscopy in Patients with Neurogenic Lower Urinary Tract Dysfunction?

Ulla Sammer; Matthias Walter; Stephanie Knüpfer; Ulrich Mehnert; Beata Bode-Lesniewska; Thomas M. Kessler

Purpose To examine the value of surveillance urethro-cystoscopy in patients with neurogenic lower urinary tract dysfunction (NLUTD) in regard to the conflicting literature as it is generally agreed that patients with NLUTD are at increased risk for bladder cancer. Materials and Methods In a cross-sectional study, a consecutive series of 129 patients (50 females, 79 males, mean age 51, range 18–88) suffering from NLUTD for at least 5 years was prospectively investigated using urethro-cystoscopy and bladder washing cytology at a single university spinal cord injury (SCI) center. Results Due to suspicious urethro-cystoscopy and/or bladder washing cytology findings, 13 (10%) of 129 patients underwent transurethral resection of the bladder lesion and/or random bladder biopsies. Overall, 9 relevant histological findings were found in 5% (7/129) of our patients: bladder melanosis (n = 1), nephrogenic adenoma (n = 3), keratinizing squamous metaplasia (n = 1), intestinal metaplasia (n = 3), and muscle-invasive adenocarcinoma of the bladder (n = 1). Conclusions Using surveillance urethro-cystoscopy, we found relevant histological findings in 5% of our patients suffering from NLUTD for at least 5 years. Thus, surveillance urethro-cystoscopy might be warranted, although the ideal starting point and frequency remain to be determined in further prospective studies.


PLOS ONE | 2016

Urodynamic Investigation: A Valid Tool to Define Normal Lower Urinary Tract Function?

Lorenz Leitner; Matthias Walter; Ulla Sammer; Stephanie Knüpfer; Ulrich Mehnert; Thomas M. Kessler

Objectives To evaluate whether urodynamic investigation (UDI), the gold standard to assess refractory lower urinary tract symptoms (LUTS), is appropriate to select healthy volunteers with apparent normal lower urinary tract function as control subjects for comparative studies. Subjects and Methods 42 healthy subjects (22 women, mean age 32±10 years; 20 men, mean age 37±12 years) without LUTS were included into this prospective single-centre cohort study. All subjects recorded a 3-day bladder diary, completed validated questionnaires regarding LUTS, and underwent neuro-urological assessment as well as free uroflowmetry. Same session repeat UDI was performed according to “Good Urodynamic Practice” recommended by the International Continence Society, but using an air-charged instead of a water-filled catheter, and evaluated by a blinded investigator. Results All 3-day bladder diaries, LUTS questionnaires, neuro-urological assessments and free uroflowmetries were within normal limits. Overall (either during the first or second UDI), same session repeat UDI revealed pathological findings in 71% (30/42): Detrusor overactivity was detected in 14% (3/22) and 30% (6/20), post void residual >100mL in 14% (3/22) and 25% (5/20), bladder outlet obstruction in 9% (2/22) and 20% (4/20) and detrusor sphincter dyssynergia in 77% (17/22) and 65% (13/20) of our women and men, respectively. Repeatability of detrusor overactivity (κ = 0.78, 95% CI: 0.54–1.02) and detrusor sphincter dyssynergia (κ = 0.77, 95% CI: 0.55–0.98) showed substantial agreement between both UDIs. All other assessed urodynamic parameters had wide 95% limits of agreement for differences in the parameters indicating poor repeatability. Conclusions More than 70% of our healthy subjects showed pathological urodynamic findings. Although UDI is the gold standard to assess refractory LUTS, it seems not to be applicable in healthy subjects to define normal lower urinary tract function. Therefore, we do not recommend using UDI to select healthy control subjects.


Urologe A | 2012

Chronisches Schmerzsyndrom des Beckens

Matthias Walter; Ulla Sammer; Thomas M. Kessler

Chronic pelvic pain syndrome (CPPS) is defined by the European Association of Urology guidelines as a non-malignant pain perceived in structures related to the pelvis of either women or men for at least 6 months without proven infection or other obvious pathology. It affects the quality of life of millions of people worldwide and has an impact similar to that reported for other chronic diseases, such as diabetes mellitus, Crohns disease and congestive heart failure. The treatment of CPPS remains a challenge despite several established first line therapies because many patients are therapy refractory. Unconventional treatments, such as neurostimulation, neuromodulation and acupuncture may be highly successful for treating CPPS and have a favorable adverse event profile. Thus, these promising therapeutic alternatives should be considered more often in daily clinical practice.


Urologe A | 2012

[Chronic pelvic pain syndrome: neurostimulation, neuromodulation and acupuncture].

Matthias Walter; Ulla Sammer; Thomas M. Kessler

Chronic pelvic pain syndrome (CPPS) is defined by the European Association of Urology guidelines as a non-malignant pain perceived in structures related to the pelvis of either women or men for at least 6 months without proven infection or other obvious pathology. It affects the quality of life of millions of people worldwide and has an impact similar to that reported for other chronic diseases, such as diabetes mellitus, Crohns disease and congestive heart failure. The treatment of CPPS remains a challenge despite several established first line therapies because many patients are therapy refractory. Unconventional treatments, such as neurostimulation, neuromodulation and acupuncture may be highly successful for treating CPPS and have a favorable adverse event profile. Thus, these promising therapeutic alternatives should be considered more often in daily clinical practice.


Scientific Reports | 2016

Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity.

Lorenz Leitner; Ulla Sammer; Matthias Walter; Stephanie Knüpfer; Marc P. Schneider; Burkhardt Seifert; Jure Tornic; Ulrich Mehnert; Thomas M. Kessler

Many of the patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity (NDO) present with chronic bacteriuria. In these patients, antibiotic prophylaxis has been widely recommended since bacteriuria might impair treatment efficacy and cause urinary tract infections (UTI) but the evidence is limited. The aim of this study was to evaluate if an antibiotic prophylaxis is needed in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections. Between 06/2012 and 12/2014, a consecutive series of 154 patients undergoing a total of 273 treatment cycles were prospectively evaluated. Before treatment urine samples were collected, patients with no clinical signs for UTI underwent onabotulinumtoxinA injections, no antibiotic prophylaxis was given. Asymptomatic bacteriuria was found in 73% (200/273 treatments). Following treatment, UTI occurred in 5% (9/200) and 7% (5/73) of patients with and without bacteriuria, respectively. Intradetrusor onabotulinumtoxinA injections were clinically and urodynamically successful in 70% (192/273). There was no association between bacteriuria and treatment-related adverse events (odds ratio 0.64, 95% CI 0.23–1.81, p = 0.4) nor between bacteriuria and therapy failure (odds ratio 0.78, 95% CI 0.43–1.43, p = 0.4). Thus, we conclude that antibiotic prophylaxis needs to be critically reconsidered in patients undergoing intradetrusor onabotulinumtoxinA injections, especially taking into account the alarming antibiotic resistance worldwide.


The Journal of Urology | 2016

MP17-15 BACTERIURIA IN PATIENTS UNDERGOING INTRADETRUSOR ONABOTULINUMTOXINA INJECTIONS FOR REFRACTORY NEUROGENIC DETRUSOR OVERACTIVITY: DO WE NEED ANTIBIOTIC PROPHYLAXIS?

Lorenz Leitner; Ulla Sammer; Matthias Walter; Stephanie Knüpfer; Marc P. Schneider; Burkhardt Seifert; Ulrich Mehnert; Thomas M. Kessler

Leitner L1, Sammer U2, Walter M2, Knüpfer S C2, Schneider M P2, Seifert B3, Mehnert U2, Kessler T M2 1. Neuro-Urology, Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital and Department of Urology, University Hospital Basel, 2. Neuro-Urology, Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital, 3. Epidemiology, Biostatistics and Prevention Institute, Department of Biostatistics, University of Zürich


Urologe A | 2012

Chronisches Schmerzsyndrom des Beckens@@@Chronic pelvic pain syndrome: Neurostimulation, Neuromodulation und Akupunktur@@@Neurostimulation, neuromodulation and acupuncture

Matthias Walter; Ulla Sammer; Thomas M. Kessler

Chronic pelvic pain syndrome (CPPS) is defined by the European Association of Urology guidelines as a non-malignant pain perceived in structures related to the pelvis of either women or men for at least 6 months without proven infection or other obvious pathology. It affects the quality of life of millions of people worldwide and has an impact similar to that reported for other chronic diseases, such as diabetes mellitus, Crohns disease and congestive heart failure. The treatment of CPPS remains a challenge despite several established first line therapies because many patients are therapy refractory. Unconventional treatments, such as neurostimulation, neuromodulation and acupuncture may be highly successful for treating CPPS and have a favorable adverse event profile. Thus, these promising therapeutic alternatives should be considered more often in daily clinical practice.


European Urology | 2016

More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned

Lorenz Leitner; Sharmistha Guggenbühl-Roy; Stephanie Knüpfer; Matthias Walter; Marc P. Schneider; Jure Tornic; Ulla Sammer; Ulrich Mehnert; Thomas M. Kessler


Neurourology and Urodynamics | 2016

Bacteriuria in patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity: Do we need antibiotic prophylaxis?

Lorenz Leitner; Ulla Sammer; Matthias Walter; Stephanie Knüpfer; Marc P. Schneider; Burkhardt Seifert; Ulrich Mehnert; Thomas M. Kessler


ics.org | 2013

Do we need surveillance cystoscopy in patients with neurogenic lower urinary tract dysfunction

Matthias Walter; Ulla Sammer; Sharmistha Guggenbühl-Roy; Dorothee Birnböck; Stephanie Knüpfer; Ulrich Mehnert; Thomas M. Kessler

Collaboration


Dive into the Ulla Sammer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge